Envista Holdings Corp
NYSE:NVST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (21.5), the stock would be worth $6.16 (76% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 90.4 | $25.94 |
0%
|
| 3-Year Average | 21.5 | $6.16 |
-76%
|
| 5-Year Average | 22.2 | $6.38 |
-75%
|
| Industry Average | 27.6 | $7.92 |
-69%
|
| Country Average | 22.9 | $6.56 |
-75%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
$4.8B
|
/ |
Jan 2026
$47m
|
= |
|
|
$4.8B
|
/ |
Dec 2026
$234.4m
|
= |
|
|
$4.8B
|
/ |
Dec 2027
$259.2m
|
= |
|
|
$4.8B
|
/ |
Dec 2028
$286.3m
|
= |
|
|
$4.8B
|
/ |
Dec 2029
$313.4m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
E
|
Envista Holdings Corp
NYSE:NVST
|
4.2B USD | 90.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.5B USD | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
157.7B USD | 25.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.9B USD | 22.5 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
85.4B USD | 24 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.4B USD | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.1B USD | 21 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.3 |
| Median | 22.9 |
| 70th Percentile | 33.2 |
| Max | 1 826 183.3 |
Other Multiples
Envista Holdings Corp
Glance View
Envista Holdings Corp., a prominent player in the dental industry, spins a captivating narrative of innovation and expertise. Emerging from a legacy rooted in the exceptional engineering standards of Danaher Corporation, Envista was formed to focus sharply on dental products and solutions. Its operational structure is divided into three main segments: Specialty Products & Technologies, Orthodontic Products, and Equipment & Consumables. With a strategic emphasis on orthodontics and endodontics, the company engineers advanced technological solutions such as clear aligners, imaging software, and digital treatment planning tools. This specialization is key to its operations, allowing Envista to cater to dental practitioners' diverse needs with products that boost the efficiency and precision of dental treatments. Revenue generation for Envista hinges upon its broad portfolio of trusted brands, including KaVo Kerr, Nobel Biocare, and Ormco, which are synonymous with quality in the dental field. Through these brands, Envista not only manufactures and sells premium dental equipment and supplies, but also provides comprehensive services from maintenance and repair to educational support. The company utilizes a robust distribution network and partners with dental service organizations globally, ensuring its products reach a wide audience. Furthermore, Envista’s commitment to research and development fuels its profitability by continually offering state-of-the-art solutions that meet the evolving demands of the dental industry. This relentless focus on innovation and customer-centric approaches underpin its financial performance, positioning Envista as a formidable force in its market.